Carbapenem-based Antibiotics Market to Register Strong Growth, on Back of Increasing Incidence of Hospital Acquired Pneumonia and Bacterial Infections
Incidence of bacterial infections is increasing rapidly across the world offering significant revenue generating opportunities for the carbapenem-based antibiotics market. Pneumonia acquired in hospital settings due to longer patient stays, is often difficult to treat and exists as the comorbidity to various chronic diseases such as cancer, organ transplant. etc. It also interferes with the disease treatment and may be fatal if not treated with broad-spectrum antibiotics such as carbapenem-based antibiotics.
As per the Center for Disease Control (CDC), people admitted to hospital settings due to various reasons such as immunosuppressive treatment and inappropriately followed infection control protocol, suffer from hospital-acquired pneumonia (HAP). Along with HAP, incidence of various bacterial diseases is increasing rapidly, which in turn is expected to drive the growth of the carbapenem-based antibiotics market.
To get an incisive view of the carbapenem-based antibiotics market, ask an analyst here
Surgery-Associated Bacterial Infection to Boost Demand for Carbapenem-Based Antibiotics
Some forms of chronic diseases often require open surgery as a treatment protocol. Before performing open surgery, carbapenem-based antibiotics are often administered as the prophylactic measure for the prevention of surgery-related bacterial infections. The World Health Organization also emphasizes on infection control protocol i.e. prophylactic administration of the carbapenem-based antibiotics that can limit or eliminate the chances of surgery-associated bacterial infection. As per WHO, 30% of global disease burden is accruing to surgery related diseases pointing towards a heightened demand for prophylactic, carbapenem-based antibiotics.
Carbapenem-based Antibiotics Market Gains Traction, with Generic Alternatives to Ertapenem to be Lucrative Revenue Pockets
Ertapenem is one of the most widely used carbapenem-based antibiotics and its patent expired in November 2017. Various regional as well as global pharmaceutical companies are assessing feasibility for possible re- launch of generic version of ertapenem in various regions. For instance, in June 2018, Aurobindo Pharma received FDA approval for generic Invanz injection. Invanz is Merck Sharp and Dohme Corp.’s joint carbapenem-based antibiotic product for the treatment of various bacterial infections. The launch of various generic version of carbapenem-based antibiotics such as ertapenem in regions such as North America and Europe is expected to offer substantial revenue generation opportunities. Lower price of generic carbapenem-based antibiotics is expected to result in increased product adoption, thus compelling carbapenem-based antibiotic manufacturers to enhance geographical footprint in lower- and middle-income countries. Increasing supply-chain operations in regions such as North America, East Asia and Europe will further give impetus to high revenue generating carbapenem-based antibiotics markets.
To get strategic and exhaustive insights on the carbapenem-based antibiotics market, request for a report sample here
Pfizer Inc., Merck Co. & Inc. and Sumitomo Dainippon Pharma Co., Ltd. are top players operating in the carbapenem-based antibiotics market. The top three players contributed more than 92% revenue share in the carbapenem-based antibiotics market in 2018. Key players are prominently focusing on increasing their carbapenem-based antibiotics availability in different countries for the treatment of a large patient pool with bacterial infections.
Carbapenem-based Antibiotics Market - Scope of Report
Fact.MR recently published a market study on the global market for carbapenem-based antibiotics. The study provides detailed assessment on the key market dynamics, including drivers, trends, opportunities restraints, and detailed information about the carbapenem-based antibiotics market structure. The market study presents exclusive information about how the carbapenem-based antibiotics market will grow during the forecast period 2019-2029.
Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market, and compounded annual growth rate (CAGR) are explained in Fact.MR’s study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of the carbapenem-based antibiotics market during the forecast period.
The study is relevant for stakeholders in the carbapenem-based antibiotics market, including carbapenem-based antibiotics products manufactures, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in the carbapenem-based antibiotics market, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in Fact.MR’s study.
The study also includes statistics as well as facts related to macroeconomic factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the carbapenem-based antibiotics market. Furthermore, small businesses and new entrants in the carbapenem-based antibiotics market too can make use of the information presented in this study, based on, which they can make appropriate business decisions to gain momentum in the carbapenem-based antibiotics market.
Key Segments of Carbapenem-based Antibiotics Market
Fact.MR’s study on the carbapenem-based antibiotics therapy market offers information divided into four important segments - product, indication, sales channel, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.
Key Questions Answered in Fact.MR’s Carbapenem-based Antibiotics Market Report
- Which regions will continue to remain the most profitable regional markets for carbapenem-based antibiotics market players?
- Which factors will essentially induce a change in the demand for carbapenem-based antibiotics in the forecast period?
- How will changing trends impact the carbapenem-based antibiotics market?
- What are key manufacturers’ strategy to enhance their product adoption and improve regional product footprints?
- Which companies are leading the carbapenem-based antibiotics market?
- What are the winning strategies of stakeholders in the carbapenem-based antibiotics market to upscale their position in this landscape?
Carbapenem-based Antibiotics Market: Research Methodology
In Fact.MR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the carbapenem-based antibiotics market, and reach conclusions on future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure accuracy and reliability of conclusions.
Secondary resources referred to analysts during the production of the carbapenem-based antibiotics market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the carbapenem-based antibiotics market, and makes Fact.MR’s projection on the growth prospects of the carbapenem-based antibiotics market more accurate and reliable.
Fact.MR offers custom research services that help clients to get specific research solutions
We are committed towards customer satisfaction and quality service.